Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin in Refractory or Relapsed AML M4/M5
NCT00559091Phase 2Completed
- Sponsor
- Jewish General Hospital
- Start
- Apr 2007
- Primary completion
- Feb 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribavirin in acute myeloid leukemia (AML), sponsored by Jewish General Hospital. Primary endpoint: Overall Response Rate at 6 months. Started Apr 2007; status: completed.
02
Drugs
ribavirin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00559091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00559091.